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Abstract
Background: Angiogenesis is considered an important factor in the pathogenesis of Rheumatoid Arthritis (RA) where it has
been proposed as a therapeutic target. In other settings, active angiogenesis is characterized by pathologic, immature
vessels that lack periendothelial cells. We searched for the presence of immature vessels in RA synovium and analyzed the
dynamics of synovial vasculature along the course of the disease, particularly after therapeutic response to TNF antagonists.
Methodology/Principal Findings: Synovial arthroscopic biopsies from RA, osteoarthritis (OA) and normal controls were
analyzed by double labeling of endothelium and pericytes/smooth muscle mural cells to identify and quantify mature/
immature blood vessels. To analyze clinicopathological correlations, a cross-sectional study on 82 synovial biopsies from RA
patients with variable disease duration and severity was performed. A longitudinal analysis was performed in 25 patients
with active disease rebiopsied after anti-TNF-a therapy. We found that most RA synovial tissues contained a significant
fraction of immature blood vessels lacking periendothelial coverage, whereas they were rare in OA, and inexistent in normal
synovial tissues. Immature vessels were observed from the earliest phases of the disease but their presence or density was
significantly increased in patients with longer disease duration, higher activity and severity, and stronger inflammatory cell
infiltration. In patients that responded to anti-TNF-a therapy, immature vessels were selectively depleted. The mature
vasculature was similarly expanded in early or late disease and unchanged by therapy.
Conclusion/Significance: RA synovium contains a significant fraction of neoangiogenic, immature blood vessels.
Progression of the disease increases the presence and density of immature but not mature vessels and only immature
vessels are depleted in response to anti-TNFa therapy. The different dynamics of the mature and immature vascular
fractions has important implications for the development of anti-angiogenic interventions in RA.
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Introduction
Increased synovial vascularity and biomarkers of angiogenesis
have been described in different chronic arthritic diseases [1–6].
Multiple inflammatory mediators such as cytokines, chemokines
and growth factors produced in excess in the synovial environment
can directly or indirectly mediate inflammatory angiogenesis
[5–7]. One of the key mediators of the inflammatory angiogenic
response is vascular endothelial growth factor (VEGF). VEGF can
be induced by hypoxia and cytokines in synovial macrophages and
fibroblasts [5–9]. Local and systemic levels of VEGF have been
found increased in rheumatoid arthritis (RA) and correlate with
active and severe disease [8–12]. In the collagen induced arthritis
murine model, different VEGF antagonists have consistently
shown remarkable therapeutic effects, pointing to angiogenesis as
a valid therapeutic target [13–15]. However, detailed morpholog-
ical studies of the changes in vascularity or vascular structure in
arthritic tissues after therapy are lacking in this model. VEGF is
also an important regulator of vascular permeability and
participates in myeloid cell migration and function [16–18].
Therefore, its antagonists might also improve arthritis by down-
regulating these processes, also highly relevant to the pathogenesis
of arthritis
VEGF mediated pathological angiogenesis has been extensively
analyzed in cancer, where VEGF antagonists have reached clinical
use and benefit patients with advanced malignancies [19]. Cancer
angiogenesis is characterized by morphologically abnormal,
immature, dilated and leaky vessels, which decrease effective
tumour perfusion and contribute to tumour development by
multiple mechanisms [20,21]. These VEGF induced immature
vessels lack proper periendothelial coverage by pericytes or smooth
muscle cells (SMC). VEGF mediates endothelial proliferation
while inhibiting pericyte and SMC development, a process instead
dependent on platelet derived growth factor (PDGF) signalling
[22,23]. Selective depletion of immature vessels has been
demonstrated after VEGF targeting in animal models of cancer,
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whereas mature vessels are relatively stable and resistant to VEGF
antagonists [20–24]. VEGF inhibition retards tumour progression
by complex effects in vascular functions, including improved
effective tumour perfusion and changes in inflammatory cell and
fluid influx [22–25].
Similar to tumours, in RA synovium, a severely hypoxic
environment is maintained despite active angiogenesis and
enhanced vascularity, suggesting abnormal function of the
neoangiogenic vessels [26,27]. However, the presence of immature
synovial vessels or their potential contribution to the disease
process has not been investigated. Improvement of the disease in
response to anti-TNF therapy is paralleled by a dramatic
reduction in local or systemic VEGF and other angiogenesis
markers [10–12,28,29]. Imaging techniques suggest that increased
vascularity and oedema are reduced by effective therapy [30–32].
Persistent vascular activity correlates with further damage to bone
and cartilage tissues even in patients on clinical remission.
Therefore, analyzing changes in vascular structure and density
after the indirect VEGF down regulation that occurs in response to
anti-TNF-a therapy might be informative on the potential role of
neoangiogenic vessels in the pathogenesis of RA.
We have specifically analyzed the pericyte/endothelial structure
of RA synovial vessels and whether changes in vascular density or
maturity correlate with clinicopathological progression of the
disease. Furthermore, we longitudinally analyzed potential chang-
es in the vascular structure in response to effective therapy in a
series of patients treated with TNF-a antagonists for active disease.
Methods
Ethics Statement
All patients signed a written informed consent. The present
study was approved by the institutional ethical committees of both
participating centers (Ethical Committee of the Hospital Clinic of
Figure 1. Detection of immature or mature blood vessels in RA synovial tissues. Double immunoflurescent labeling of endothelium (CD31,
red fluorescence) and pericytes/smooth muscle cells (aSMA, green fluorescence) in normal and RA synovial tissue is shown. Original magnification
6400. Right panels show the same area as in middle panels with higher magnification. Mature CD31+ vessels covered by aSMA+ periendothelial cells
are marked by arrows, and immature CD31+ vessels lacking aSMA+ mural cells by arrow heads.
doi:10.1371/journal.pone.0008131.g001
Table 1. Mature and Immature Vessels in RA, OA or Normal Synovial Tissues.
RA n = 82 OA n = 14 Normal n = 4 p-value*
CD31+/aSMA+ Vessels/mm2 294695 74628 94644 ,0.0001
CD31+/aSMA– Vessels/mm2 26627 0.661.2 060 ,0.0001
Total Vessels/mm2 319698 74.5628 94644 ,0.0001
Proportion of tissues with CD31+/aSMA– vessels (%) 66/82(80%) 3/14(21%) 0/4(0%) ,0.0001
CD31+/aSMA+: Mature vessels; CD31+/aSMA–: Immature vessels; Total vessels represents the sum of both mature and immature vessels.
(*) RA versus OA.
doi:10.1371/journal.pone.0008131.t001
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Barcelona, Barcelona, and Clinical Research Ethics Committee of
the Hospital 12 de Octubre, Madrid, Spain).
Patients and Synovial Biopsies
Arthroscopic synovial tissue biopsies were obtained from the
knee of 82 patients fulfilling the American Rheumatism Associ-
ation revised criteria for RA. All patients had active disease
characterized by inflammation of at least one knee joint. Patients
characteristics at biopsy, including age, sex, disease duration, 28-
joint Disease Activity Score (DAS28), C-reactive protein and
erythrocyte sedimentation rate (ESR), presence of IgM rheuma-
toid factor (RF) (positive$30 IU/ml) or anti-citrullinated protein
antibodies (ACPA) as determined by second-generation enzyme-
linked immunosorbent assay (positive$50 IU/ml, Immunoscan,
Stockholm, Sweden), and the presence of erosions were recorded.
A subgroup of 25 patients that started an anti-TNF-a therapy
(etanercept, adalimumab or infliximab) at first biopsy due to active
disease refractory to previous DMARD therapy (mean DAS28
score 6.061.4), underwent a second biopsy after 1062 months of
anti-TNF-a therapy. All these patients also received DMARD
therapy with methotrexate (7.5–20 mg/week) and 60% low dose
prednisone (#5 mg/day). Arthroscopic biopsies were obtained for
research purposes as previously described (33). The rate of side
effects of arthroscopy was very low and restricted to delayed
wound healing of one of the portals of entry in one patient (,1%).
After arthroscopy, lavage and steroid injection were performed
and usually followed by rapid improvement of arthritic pain.
Control synovial tissues from 14 osteoarthritic (OA) synovial
tissues were obtained by synovectomy at prostetic join replacement
surgery. In addition, normal (non-inflammatory) synovial tissues
were obtained from 4 individuals lacking previous joint disease at
elective arthroscopic surgery for minor traumatic lesions. Lack of
inflammatory infiltration in these tissues was confirmed by
histological examination.
Immunofluorescent Labelling of Synovial Vessels
Tissues were deparafinized, rehydrated and microwave heated
in pH 9 EDTA for antigen retrieval. Double immunofluorescent
labeling of endothelium and periendothelial pericytes/smooth
muscle cells was performed by sequential incubation with anti-
CD31 (JC70A clone, Dako, Carpinteria, CA, USA) and anti-a-
smooth muscle actin (aSMA) (1A4 clone, Sigma Aldrich Quı́mica,
Madrid, Spain) monoclonal antibodies, and isotype specific Alexa
488 and Alexa 594 labeled secondary antibodies (Molecular
Probes, Invitrogen, Eugene, OR). Sections were counterstained
with 49,6-diamidino-2-phenylindole (DAPI). Immunoperoxidase
staining of T-cells, B-cells, macrophages and PNAd+ high-
endothelial venules (HEV) was performed and quantified as
previously described [33]. Lymphoid neogenesis was defined by
the presence of grade 2–3 T/B cell aggregates containing HEV as
described [33].
For lymphatic vessels, immunoperoxidase labeling was per-
formed with anti-podoplanin mAb (D2/40 clone, Dako) and
avidin-biotin immunoperoxidase secondary reagents (Vector
Laboratories, Burlingame, CA, USA), and developed by diami-
nobenzidine chromogen. Double lymphatic and CD31 labeling
was performed by simultaneous podoplanin immunoperoxidase
and CD31 immunofluorescent detection as indicated above.
The whole area of each tissue was photographed and digitalized
using a Spot RT CCD camera and Spot 4.0.4 software (Diagnostic
Instruments, Sterling Heights, Michigan) on a Zeiss Axioplan-2
fluorescence microscope (Zeiss, Jena, Germany). The number of
blood vessels per area was determined by two independent
observers blind to the origin and characteristics of each biopsy.
Interobserver correlation coefficient for CD31+/aSMA- number
of vessels was r = 0.75 (p,0.0001, Spearman’s test). The
proportion of labeled/unlabeled synovial tissue area was also
analyzed in digitalized images using ImageJ software (http://rsb.
info.nih.gov/ij).
Statistical Analyses
For cross-sectional analyses, quantitative variables were com-
pared by Mann Whitney U test or ANOVA (Kruskall Wallys test)
Figure 2. Double labeling of lymphatic and CD31-positive
vessels in RA synovial tissues. Lymphatic vessels were detected by
immunoperoxidase (brown immunostaining) detection of podoplanin
and double immunofluorescent labeling (red fluorescence) of CD31.
The same field was photographed by light or fluorescent microscopy to
show the position of CD31+ (arrowheads) and podoplanin+ vessels
(arrows). Light microscopy image was inverted and merged with CD31
fluorescent image of the same field to show the relative position of
podoplanin (blue) and CD31 (red) labeling.
doi:10.1371/journal.pone.0008131.g002
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where appropriate. Correlation between different numerical
variables was analyzed by Spearman’s test. Changes in quantita-
tive variables before and after anti-TNF therapy were tested with
Wilcoxon’s signed rank test for paired data. Bonferroni correction
was applied for the correction of multiple testing.
Results
Vascularity and Immature aSMA-Negative Blood Vessels
in RA Synovial Tissues
By double labelling of endothelium (CD31) and pericyte/
smooth muscle cells (aSMA) immature, CD31-positive vessels
lacking aSMA-positive periendothelial cells, and mature CD31-
positive vessels covered by aSMA-positive mural cells were
identified in RA synovial tissues (Figure 1). Most RA tissues
(66/82) contained a variable number of immature CD31+/aSMA-
vessels, whereas they were only present in a small proportion of
OA tissues at a significantly lower density, and were not identified
in normal synovial tissues (Table 1). RA immature vessels were
predominantly small size vessels, preferentially located in sublining
areas containing abundant inflammatory infiltrates. Complete or
partial concordance in the presence of immature vessels in
different areas of the same joint was 30% and 53% respectively,
whereas in 17% of the cases, only one area contained immature
vessels.
The fractional CD31-positive and aSMA-positive areas and the
total number of mature vessels per area were also significantly
increased in RA tissues compared to OA and normal tissues
(Table 1). Although both determinations are not equivalent, since
labelled area depends on number and size of vessels, statistically
significant correlation was confirmed between manually acquired
quantitative data on CD31- or aSMA-positive vessels per area and
the fractional CD31- or aSMA-positive area evaluated by digital
image analysis (r = 0.35, p = 0,001 and r = 0.31, p = 0.002
respectively).
Weak CD31 labelling has occasionally been found in lymphatic
vessels of different tissues [34]. Although erythrocytes could be
observed in some immature vessels lumen by light phase contrast
microscopy (data not shown), to formally exclude that increased
lymphatics in RA could explain the presence of CD31 vessels
Figure 3. Clinicopathological correlations of immature blood vessels in RA synovial tissues. Disease duration, DAS28 score, erosive
disease, and synovial tissue infiltration by CD3, CD20 or CD68 cells is shown in groups with (+) or without (2) immature vessels as indicated. Density
of mature or immature vessels in patients stratified by disease duration and levels of activity (low: DAS28,3.2, moderate 3.2–5.1, or high.5.1).
Spearman’s correlation coefficients between immature vessels density and disease duration, DAS28, CD3 or CD20 infiltration are shown. (*) p,0.05
(see text). " p = 0.04 (Kruskall Wallys test and post hoc Dunns test (low versus moderate or high activity groups).
doi:10.1371/journal.pone.0008131.g003
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lacking aSMA-positive periendothelial cells, we performed double
CD31 and lymphatic (podoplanin) immunolabelling. Podoplanin
was detected by peroxidase immunohistochemistry due to lower
sensitivity of immunofluorescent labelling. Podoplanin immuno-
peroxidase and CD31 immunofluorescent labelling were mutually
exclusive, therefore confirming that in RA synovial tissues,
CD31+/aSMA- were immature blood vessels (Figure 2).
Clinicopathological Correlations of Immature Blood
Vessels in RA Synovial Tissues
Our RA patients represented a non-selected cross-sectional
sample, heterogeneous in terms of disease duration, and
demographic, clinical and analytical characteristics. We analysed
whether selected characteristics of the disease, particularly disease
duration and several markers of activity or severity, were
correlated with the presence or abundance of immature vessels
in synovial tissue (Table 2). The presence of immature vessels was
significantly associated to a significantly longer disease duration
(1016104 versus 7.863.6 months; p,0.0001; Table 2; Figure 3).
The density of immature blood vessels was also significantly and
positively correlated with the duration of the disease (p = 0.003;
Figure 3). In contrast, the mature vascular density did not correlate
with disease duration (Figure 3). The different density of immature
and mature vessels stratified by different disease duration segments
is shown in Figure 3.
Disease activity at biopsy as evaluated by DAS28 score was
slightly higher in patients with synovial immature vessels (5.261.5
versus 4.760.8; Table 2 and Figure 3) but the difference did not
reach statistical significance. The density of immature vessels was
significantly lower in low versus moderate and high disease activity
groups as shown in Figure 3 (p = 0.04). The density of immature
blood vessels was also significantly and positively correlated with
the DAS28 score (p = 0.009; Figure 3). Mature vascular density
was not correlated with disease activity.
The presence of erosive disease at the time of biopsy was
significantly higher in the group of patients with synovial
immature vessels (78% versus 40%; p = 0.0039; Table 2).
Stratification by sex, age, presence or absence of RF or ACPA
auto-antibodies, did not show differences in the presence or
density of immature vessels nor in mature vascular density in the
different groups (Table 2).
Synovial inflammation was also quantified as the density of
cellular infiltration by macrophages, T-cells, B-cells, or their
organization into lymphoid aggregates characterized as lymphoid
neogenesis (LN) as previously described (33). Correlation between
these parameters and the presence or density of immature vessels
was analysed. Tissues containing immature vessels contained a
higher density of T and B-cells and macrophages (Table 2;
Figure 3). A significant correlation between the density of T-cells
(p,0.0001) but not sublining macrophage infiltration and the
density of immature vessels was found (Figure 3). Density of B-cells
and the presence of LN structures were higher in tissues with
immature vessels but after correction for multiple testing the
difference was non-significant. No significant correlation between
mature vascular density and cell infiltration by any cell type or LN
structures was found.
Effects of Anti-TNF Therapy on Mature and Immature
Blood Vessels
To evaluate whether the structure or abundance of immature
vessels was modified by therapy and whether these changes
correlate with changes in the clinical course of the disease induced
by therapy, we analysed a subgroup of 25 patients rebiopsied after
anti-TNFa therapy. Clinical and synovial cellular changes in
response to therapy in this group of patients are shown in Table 3.
After therapy, a significant improvement in DAS28 scores was
observed, as well as a significant decrease in T-cell and
macrophage cell infiltration, and a non-significant decrease in B-
cell infiltration (Table 3). Seven patients had not responded, and 6
and 12 had obtained moderate and good EULAR responses to
anti-TNF-a therapy at the time of the second biopsy [35].
A statistically significant decrease in the number of CD31+/
aSMA- immature vessels was observed in biopsies obtained after
anti-TNF-a therapy (Table 3). In contrast, the number of mature
CD31+/aSMA+ vessels per mm2 was not significantly modified
after therapy (Table 3). Consistently, the fractional CD31 area was
Table 2. Clinicopathological data stratified by the presence of Immature Vessels (IV).
All patients n = 82 IV- n = 16 (20%) IV+ n = 66 (80%) p-value*
Age (years) 58613 53610 59610 NS
Female (%) 68% 69% 68% NS
RA duration (months) 836100 7.863.6 1016104 ,0.0001
DAS28 5.161.4 4.760.8 5.261.5 NS
CRP (mg/dl) 4.0263.43 3.0862.92 4.2563.50 NS
Erosive disease (%) 67% 40% 78% 0.0039
Auto-antibodies positive{ (%) 71% 65% 72% NS
CD3+ T-cells/mm2 6676466 2586239 7426460 0.0002
CD20+ B-cells/mm2 2266205 87698 2516211 NS"
CD68+ cells/mm2 164361326 99061037 172961336 NS
LN (%) 48% 29% 52.4% NS"
Mature Vessels/mm2 294695 2796111 298692 NS
Data represent baseline data recorded at the time of biopsy. IV: immature CD31+/aSMA– vessels. LN: lymphoid neogenesis; DAS28: disease activity score; CRP: C-reactive
protein; NS: Non-significant.
(*)IV- versus IV+ groups.
({)RF or ACPA auto-antibodies.
(")p,0.05 but NS after correction for multiple testing.
doi:10.1371/journal.pone.0008131.t002
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significantly decreased after therapy whereas the aSMA area was
not modified (Table 3). The relative decrease in immature vessels
density was higher in patients obtaining better EULAR therapeu-
tic responses (p = 0.01; Figure 4). Clinical and pathological
changes in responders and non-responders are also shown in
Table 3.
Discussion
The presence of immature blood vessels is a phenomenon
previously associated to cancer tissues or developmental processes
where active angiogenesis takes place [21,36]. An imbalance
between endothelial cell tube formation and the parallel
development of pericytes has been mechanistically linked to
VEGF-induced angiogenesis [23]. In RA, a severely hypoxic
environment and possibly cytokines, induce Hif (hypoxia inducible
factor) mediated transcriptional activation of VEGF and many
other pro-angiogenic genes [10,26,27,37]. Excessive expression of
VEGF in chronically inflamed RA synovial tissue is therefore one
of the key factors explaining increased angiogenesis in the synovial
membrane [5–9]. Consistently, we found abundant immature
blood vessels in the inflammatory RA tissue which represents the
first description of this vascular abnormality in a human chronic
inflammatory disease. Scanty immature vessels could also be
detected in a few OA but not in normal synovial tissues. This
suggests that active angiogenesis and the presence of immature
vessels is not a disease-specific process but it is rather associated to
the severity of inflammation. In OA, a less intense inflammatory
process and active vascular remodelling are also variably present
[2–4]. In a previous study we found that increased VEGF
expression also characterizes OA synovial fibroblasts [38]. In RA,
immature vessels seem to appear relatively early in the disease but
as disease progresses their density increases, being maximal in
long-standing, active, and erosive disease groups. The observed
correlation between lymphocyte infiltration and immature vessels
formation points to a possible link between both processes.
Among patients rebiopsied after anti-TNF-a therapy, immature
vessels depletion was preferentially observed in those patients
achieving good therapeutic responses. The important increase in
mature vessels density observed in RA tissues seems present from
the earliest phases and less susceptible to change. After anti-TNF-a
therapy, the observed decrease in immature vessels was not
paralleled by a reduction in mature vasculature. Consistently, only
CD31 but not aSMA labelled area was decreased by anti- TNF-a
therapy. These observations together with previous observations
on the effect of therapy on local or systemic angiogenesis markers
suggests that effective therapy halts active angiogenesis but has
little effect on the expanded mature vascular bed [10,28,29].
In the most refractory patients, immature vascular development
seems insufficiently targeted by anti-TNF-a therapies. Persistently
enhanced vascularity after improvement of clinical inflammation
can be a factor of chronicity and it has been associated to further
progression of joint damage [30–32]. Whether the persistent
vascular signal observed by imaging studies corresponds to
resistant immature or to higher mature vascularity is not known.
Parallel imaging and histological studies are needed to evaluate the
contribution of persistent immature/mature vessels to disease
progression and may illustrate the specific pathogenetic contribu-
tion of immature vessels.
In cancer tissues, specific anti-angiogenic anti-VEGF therapy
has been found to induce selective changes in the immature
vascular bed, a process called vascular normalization, where
immature vessels selectively disappear [21,24]. This is consistent
with the different sensitivity to VEGF depletion of immature and
mature vessels. Whereas VEGF is required to sustain newly
Figure 4. Variation in the density of immature vessels stratified
by the levels of response to anti-TNF-a therapy. Decrease in
immature (left graphics) or mature (right graphics) vessels density
between the first and second biopsy after anti-TNF-a therapy is shown
stratified by EULAR responses: 0 = : No response; 1: Moderate response;
2: Good response. (*) Kruskall Wallys test and post hoc Dunns test (non-
responders versus good responders).
doi:10.1371/journal.pone.0008131.g004
Table 3. Clinicopathological changes in patients after anti-TNFa therapy.
Basal Biopsy Post Anti-TNF Biopsy p-value D Change Non-responders* D Change Responders
DAS28 6.061.4 3.961.9 ,0.0001 20.560.7 3.261.8
CRP mg/dl 4.863.5 1.662.0 0.0004 1.064.1 4.263.6
CD31+/aSMA– vessels/mm2 52631 31627 0.017 20.4613 12616
CD31 area (%) 3.161.6 2.561.4 0.03 20.262.1 0.961.0
CD31+/aSMA+ Vessels/mm2 276682 3216110 NS 30625 8659
aSMA+ area (%) 3.6861.6 3.6061.4 NS 20.161.9 0.161.7
CD3/mm2 823688 478683 0.0064 2026398 4006698
CD20/mm2 322659 220654 NS 2196245 566411
CD68/mm2 324638 192631 0.0091 536180 1636195
CD31+/aSMA–: immature vessels. CD31+/aSMA+: mature vessels. p-value of basal versus post-anti-TNF values.
(*)Absolute decrease from basal values in patients achieving moderate or good EULAR response (responders) and non responders to anti-TNF.
doi:10.1371/journal.pone.0008131.t003
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formed vessels, this factor is dispensable for the mature vascular
network [21]. Our data suggest that upon indirect VEGF down-
regulation by anti-TNF-a therapy in RA [10–12], blood vessels
normalization rather than global vascular reduction occurs, and
suggests that VEGF antagonists might not be active on the largest
fraction of the expanded synovial vascularity. In an animal model
of airway inflammatory angiogenesis, VEGF independent angio-
genic effects of TNF-a have also been identified, suggesting that
alternative mediators may also be linked to the down-regulation of
inflammatory angiogenesis induced by TNF-a blocking [39].
Although immature vessels depletion occurred preferentially in
patients responding to anti-TNF-a therapy, the pleiotropic effects of
this intervention do not permit to speculate on the role of immature
vessels depletion in such response. In cancer, immature vessels are
associated to increased permeability and high interstitial fluid
pressure, decreasing the effective perfusion of the tissue and drug
access, and modifying inflammatory cell infiltration [20–22,25].
The role of immature vessels in inflammation has only been
explored in a murine model of Mycoplasma induced airway
inflammation [40]. In this model, enforced vascular immaturity by
ephrinA2 deletion was directly linked to greater leukocyte
infiltration and higher expression of inflammatory cytokines upon
inflammatory challenge. Further studies on the specific contribu-
tion of immature blood vessels to RA pathogenesis are needed to
understand the potential of more specific anti-angiogenic inter-
ventions for the therapy of RA.
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29. Cañete JD, Pablos JL, Sanmartı́ R, Mallofré C, Marsal S, et al. (2004)
Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with
infliximab in psoriatic arthritis. Arthritis Rheum 50: 1636–41.
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